Drugs / JS107
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05502393 | Jul 2022 → Jul 2024 | cancer | Shanghai Junshi Bioscience Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05657418 | Mar 2022 → Jan 2025 | malignant pancreatic neoplasm | Shanghai Junshi Bioscience Co., Ltd. | Terminated | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07584135 | May 2026 → Jan 2029 expected | gastric adenocarcinoma | NingBo Junyan Hongshi Biosciences Co., Ltd | Recruiting | No outcome recorded |
| Phase 3 | NCT07284134 | Dec 2025 → Oct 2027 expected | gastroesophageal adenocarcinoma | Shanghai Junshi Bioscience Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JS107 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07284134 ↗ |
| Route | Intravenous | “JS107, i.v., q3w” NCT05502393 ↗ |